Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours

NCT01060423 is registered in ClinicalTrials.gov with Hans-Joachim Schmoll, MD as lead sponsor.

NCT NCT01060423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01060423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours
Lead sponsor
Hans-Joachim Schmoll, MD
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2010
Completion date
May 31, 2015
Enrollment
8 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer